In conclusion, our findings indicate that the immune status at baseline and EOT affected treatment outcomes in patients treated with T-DM1, whereas the treatment efficacy of T-DXd in patients with HER2-positive breast cancer can be achieved regardless of immune status. The gene discussed is ERBB2; the disease is breast cancer.